Zhengye Biotechnology Holding Ltd (ZYBT) FinancialsZYBTZhengye Biotechnology Holding Ltd

Evaluating the bottom line, Zhengye Biotechnology Holding Ltd maintains a gross margin of 20.51%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -60.59%, while the net margin is -71.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ZYBT converts its operational activities into shareholder value.

In the context of the broader market, ZYBT competes directly with industry leaders such as BCTX and ELUT. With a market capitalization of $42.22M, it holds a leading position in the sector. When comparing efficiency, ZYBT's gross margin of 20.51% stands against BCTX's N/A and ELUT's 59.62%. Such benchmarking helps identify whether Zhengye Biotechnology Holding Ltd is trading at a premium or discount relative to its financial performance.

Zhengye Biotechnology has shown inconsistent financial performance, with total revenue of 27.02 million CNY in Q3 2025, but a significant net loss of 24.06 million CNY during the same period. The gross margin has also declined sharply to 8.30%, which is concerning for long-term profitability.